Caitlin Raymond: When to Use Albumin vs. Plasma, and Why the Timing Matters
Caitlin Raymond, a board-certified Clinical Pathologist and current Transfusion Medicine Fellow at the National Institutes of Health, shared on LinkedIn:
“The Overlooked Half of the Exchange
When we talk about plasma exchange, most discussions stop at what we’re removing — antibodies, paraproteins, cytokines. But that’s only half the story.
Replacement fluid is the other half — and it quietly dictates safety, hemostasis, and recovery.
The right choice isn’t just technical; it’s clinical judgment in action.
In my latest blog post, I break down:
- When to use albumin vs. plasma, and why the timing matters
- How combination strategies (like 50:50 albumin–FFP) can balance practicality and bleeding risk
- Common myths and misconceptions — including why “albumin is always safer” isn’t true
Real-world scenarios: TTP, transplant desensitization, AMR, and more
Read the full post here.
Choosing the replacement fluid isn’t just following a protocol — it’s the art within the algorithm.
ecause in apheresis, the machines may be automated, but judgment isn’t.”
Stay updated with Hemostasis Today.
-
Jul 13, 2026, 11:25Luisa Müller: Advancing Anticoagulation Strategies for VITT at ISTH 2026
-
Jul 13, 2026, 10:49Joshua Zeidner: Advancing Menin Inhibitor Therapy in MD Education AML-ALL US Focus 2026
-
Jul 13, 2026, 10:25Flora Peyvandi: A Practical Approach to ALT Elevation After Gene Therapy at ISTH 2026
-
Jul 13, 2026, 10:02Jessica Garcia: Where Science and Community Come Together at ISTH 2026
-
Jul 13, 2026, 09:46Fabrice Cognasse: Is There Such a Thing as the Perfect Platelet Product?
-
Jul 13, 2026, 09:42Cancer-Associated Arterial Thromboembolism: Redefining the Thrombotic Burden in Oncology
-
Jul 13, 2026, 05:59Connecting and Collaborating at ISTH 2026 – NNHF
-
Jul 13, 2026, 05:58Lara Monica: Back at ISTH – Looking Forward to Science and Reconnections!
-
Jul 13, 2026, 05:57Barbara Adams Krolak: Exciting Updates From the ISTH 2026 Regulatory Session